ArticleMalaria research and treatment2014
Antirelapse Efficacy of Various Primaquine Regimens for Plasmodium vivax.
Article in Malaria research and treatment, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis.The Lancet. Infectious diseases · 2024Pooled it
- Safety and efficacy of primaquine in patients withBMJ global health · 2023Pooled it
- Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria.The Cochrane database of systematic reviews · 2019Pooled it
- Therapeutic efficacy of alternative primaquine regimens to standard treatment in preventing relapses by Plasmodium vivax: A systematic review and meta-analysis.Colombia medica (Cali, Colombia) · 2015Pooled it
- 14 days of high-dose versus low-dose primaquine treatment in patients with Plasmodium vivax infection in Cambodia: a randomised, single-centre, open-label efficacy study.The Lancet. Infectious diseases · 2025Trial
- Seven-day versus fourteen-day low-dose primaquine forThe Lancet regional health. Southeast Asia · 2026Article
- Effect of higher dose primaquine for the radical cure ofThe Lancet regional health. Western Pacific · 2026Article
- High versus low dose of 14 days treatment of primaquine inmedRxiv : the preprint server for health sciences · 2025Article
- Article
- Article
- Factors influencing severity of recurrent malaria in a conflict-affected state of South Sudan: an unmatched case-control study.Conflict and health · 2022Article
- Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro.Scientific reports · 2021Article
- Population Pharmacokinetics of Primaquine in the Korean Population.Pharmaceutics · 2021Article
- Prevalence and association of malaria with ABO blood group and hemoglobin level in individuals visiting Mekaneeyesus Primary Hospital, Estie District, northwest Ethiopia: a cross-sectional study.Parasitology research · 2021Article
- Towards the elimination of Plasmodium vivax malaria: Implementing the radical cure.PLoS medicine · 2021Review
- Plasmodium vivax in the Era of the Shrinking P. falciparum Map.Trends in parasitology · 2020Review
- Prevalence of malarial recurrence and hematological alteration following the initial drug regimen: a retrospective study in Western Thailand.BMC public health · 2019Article
- 8-Aminoquinoline Therapy for Latent Malaria.Clinical microbiology reviews · 2019Review
- Primaquine 30 mg/day versus 15 mg/day during 14 days for the prevention of Plasmodium vivax relapses in adults in French Guiana: a historical comparison.Malaria journal · 2018Article
- Severe vivax malaria: a prospective exploration at a tertiary healthcare centre in Southwestern India.Pathogens and global health · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Background. Efficacy of standard dose of primaquine (PQ) as antirelapse for P. vivax has decreased. We aimed to assess efficacy of different PQ regimens. Methods. It was an open label, randomized, controlled, parallel group, assessor blind study comparing antirelapse efficacy of 3 PQ regimens (B = 15 mg/day × 14 days, C = 30 mg/day × 7 days, and D = 30 mg/day × 14 days) with no PQ group (A) in P. vivax patients. Paired primary and recurrence samples were subjected to 3 methods: (i) month of recurrence and genotyping, (ii) by PCR-RFLP, and (iii) PCR sequencing, to differentiate relapse and reinfection. The rates of recurrence relapse and reinfection were compared. Methods were compared for concordance between them. Results. The recurrence rate was 16.39%, 8.07%, 10.07%, and 6.62% in groups A, B, C, and D, respectively (P = 0.004). The relapse rate was 6.89%, 1.55%, 4%, and 3.85% as per the month of recurrence; 8.2%, 2%, 4.58%, and 3.68% (P = 0.007) as per PCR-RFLP; and 2.73%, 1.47%, 1.55%, and 1.53% as per PCR sequencing for groups A, B, C, and D, respectively. The concordance between methods was low, 45%. Conclusion. The higher recurrence rate in no PQ as compared to PQ groups documents PQ antirelapse activity. Regimens tested were safe. However, probable resistance to PQ warrants continuous monitoring and low concordance and limitations in the methods warrant caution in interpreting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.